DHR Stock Analysis — Danaher Corporation
Sector: Healthcare
AI Verdict
Danaher trades at 21.9x next year's earnings while analysts expect a 66.6% EPS jump — that's cheap for the growth on offer if its recurring-revenue moat holds, but the overbought RSI means short-term buyers risk a sharp pullback.
Competitive Moat
Danaher owns a portfolio of specialized life sciences and diagnostics businesses, many of which operate in highly regulated niches with high switching costs for customers. Its proprietary technologies and recurring consumables revenue create a sticky customer base that is hard for competitors to disrupt.
Summary
Danaher is notable right now for a projected 66.6% jump in earnings next year, which is rare among large healthcare names.
Where It Stands
Danaher has delivered a -1.60% return over the past year, trades at 21.9x next year's earnings (below the healthcare sector median of 22x), and its RSI of 70.4 signals elevated pullback risk.
Key Metrics
- RSI: 70.4 — Overbought
- Trailing P/E: 36.5x
- Forward P/E: 21.9x
- PEG Ratio: 0.54
- Earnings Growth: +0.7%
- Revenue Growth: +0.0%
- Market Cap: $144.7B
- Dividend Yield: 0.01%
- 1-Year Return: -1.60%
- 52-Week High: $242.80
- 52-Week Low: $160.93
Analyst Consensus
27 Buy · 5 Hold · 0 Sell (32 analysts)
Bull Case
With forward EPS growth expected at 66.6% and a forward P/E of 21.9x, you're paying a below-average price for unusually high earnings growth.
Bear Case
The RSI at 70.4 means the stock is overbought, so even a modest pullback to a neutral RSI could erase recent gains.
Catalyst to Watch
Watch for quarterly earnings — if the company delivers on the 66.6% EPS growth forecast, the current valuation could quickly look cheap.